Endogenous TRPV1 agonists such as oxidized linoleic acid metabolites (OLAMs) and the enzymes releasing them [eg, cytochrome P450 (CYP)] are up-regulated after inflammation in the rat. However, it is not known whether such agonists are elevated in human inflammatory pain conditions. Because TRPV1 is expressed in human dental pulp nociceptors, we hypothesized that OLAM-CYP machinery is active in this tissue type and is increased under painful inflammatory conditions such as irreversible pulpitis (IP). The aim of this study was to compare CYP expression and linoleic acid (LA) metabolism in normal vs inflamed human dental pulp. Our data showed that exogenous LA metabolism was significantly increased in IP tissues compared to normal tissues and that pretreatment with a CYP inhibitor, ketoconazole, significantly inhibited LA metabolism. Additionally, extracts obtained from LA-treated inflamed tissues evoked significant inward currents in trigeminal ganglia neurons and were blocked by pretreatment with the TRPV1 antagonist IRTX. Moreover, extracts obtained from ketoconazole-pretreated inflamed tissues significantly reduced inward currents in trigeminal ganglia neurons. These data suggest that LA metabolites produced in human inflamed tissues act as TRPV1 agonists and that the metabolite production can be targeted by CYP inhibition. In addition, immunohistochemical analysis of 2 CYP isoforms, CYP2J and CYP3A1, were shown to be predominately expressed in immune cells infiltrating the inflamed dental pulp, emphasizing the paracrine role of CYP enzymes in OLAM regulation. Collectively, our data indicate that the machinery responsible for OLAM production is up-regulated during inflammation and can be targeted to develop potential analgesics for inflammatory-induced dental pain. Ó
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Introduction
Transient receptor potential vanilloid 1 (TRPV1) is the capsaicin-sensitive cation channel expressed on a major subclass of nociceptors. It is activated by heat as well as endogenous ligands including protons and certain lipids, and it is sensitized by inflammatory mediators such as bradykinin, prostaglandins, and nerve growth factor [6,9,15,33,37]. Recently, our group reported a novel class of lipids as specific TRPV1 agonists released upon peripheral thermal and inflammatory insults in rodent models [30, 31, 35] . These lipids are oxidized metabolites of linoleic acid (OLAMs), namely 9-HODE, 13-HODE, and their corresponding oxometabolites. In addition, we have also shown that OLAM synthesis could be regulated by certain cytochrome P450 (CYP) enzymes in a rat model of inflammation [35, 36] . Collectively, these preclinical studies indicate that inflammation triggers the release of endogenous oxidized lipids that act as TRPV1 agonists and contribute to allodynia and hyperalgesia.
However, it is not known whether the OLAM-CYP system is active in humans with inflammatory pain. Accordingly, we evaluated activity of the OLAM system and CYP expression in dental pulp tissues collected from patients with either painful IP or normal healthy teeth. IP originates as a localized inflammatory response to bacterial invasion of the pulp-dentin complex [3,12,17,28], leading to an influx of neutrophils, macrophages, and other immune cells and local release of inflammatory mediators such as bradykinin, prostaglandins, nerve growth factor, and cytokines [25] . IP is characterized by acute and often intense thermal and mechanical allodynia and hyperalgesia that may be difficult to control with
